Ovarian
REJOICE-Ovarian01
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Trial overview
Clinical Area
Medical oncology
Disease / Condition
Ovarian cancer
Study Phase
ll/lll
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)